Navigation Links
Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company
Date:3/8/2011

0;Cellceutix owns the rights to eight drug compounds, including Kevetrin, which it is developing as a treatment for certain cancers, KM-133, for the treatment of psoriasis, and KM-391, for the treatment of autism.  More information is available on the Cellceutix web site at www.cellceutix.com.

Kevetrin, KM133, and KM-391 have not been studied in humans at this time. The Company's positive results in animal studies do not necessarily guarantee success in humans, though they may form the basis for beginning Phase 1 trials.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by Cellceutix Corporation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading
'/>"/>

SOURCE Cellceutix Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cellceutix Discovers Drug Activates Guardian Angel p53 in Fight Against Leukemia
2. Cellceutix Cancer Drug Kevetrin™ Shows No Genotoxicity in Study
3. Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results
4. Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
5. RBC Life Sciences Reports Sales and Earnings Growth in 2010
6. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results
7. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
8. IRIDEX Reports Strong Growth and Profits in 2010 Fourth Quarter
9. China Pharma Holdings, Inc. Reports Full Year 2010 Financial Results
10. Sequenom Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11. Assured Pharmacy Reports Same Store Sales for the Month of December 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015  ResMed Inc. (NYSE: RMD ) today announced ... the quarter was $423.0 million, a 10 percent increase compared ... increase on a constant currency basis). Net income was $91.2 ... ended December 31, 2013. Diluted earnings per share for the ...
(Date:1/22/2015)... SAN DIEGO , Jan. 22, 2015  Profil Institute ... focused on diabetes and obesity, announced today a new ... Drug Development,  published by Springer, a leading global scientific ... extensively analyze and illustrate techniques for use in early ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/w25xpc/allergy ) has announced the ... Product & by End User - Global Forecast to 2019" ... allergy diagnostics market is valued at $1,228.58 million in 2014 ... to reach $2,230.72 million by 2019. Allergy diagnostics is used ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3
... Cellular Dynamics International (CDI) today announced the online ... demonstrating for the first time a methodology for ... banked blood samples through the creation of induced pluripotent ... lymphoblastoid B-cell lines reprogrammed to EBV-free induced pluripotent stem ...
... 2011 Reportlinker.com announces that a new ... catalogue: Product Profiles: Multiple ... market entrants http://www.reportlinker.com/p0564421/Product-Profiles-Multiple-Sclerosis---Gilenya-raises-bar-for-new-market-entrants.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... Beginning with the recent approval ...
Cached Medicine Technology:Cellular Dynamics International Unlocks the Potential of Banked Blood Samples 2Reportlinker Adds Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants 2Reportlinker Adds Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants 3Reportlinker Adds Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants 4Reportlinker Adds Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants 5
(Date:1/22/2015)... Calif. (PRWEB) January 22, 2015 ... Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were ... their leadership in advancing biotechnology, biomedical science, medical ... and Olsen each received the “2014 Life Sciences ...
(Date:1/22/2015)... years since the release of their debut recording Love is King, ... & Matthew Love – the duo are pleased to announce their ... Swan Records on February 24, 2015. , THE ROAD offers the ... all of us to walk out of the mire of our ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 As ... of overall health care gains momentum worldwide, Rev. Eric ... HealthCare Chaplaincy Network (HCCN), will be the keynote ... spiritual care in Israel’s public health system. , The conference, ...
(Date:1/22/2015)... Lower-Auto-Insurance.com has released a new blog post explaining the importance of ... the costs of an auto insurance policy . , Clients ... prices for their vehicle insurance policies. The safety a vehicle offers ... Because of this, drivers should always carry a first aid ...
(Date:12/26/2014)... TX (PRWEB) December 26, 2014 The US ... in this report. In 2013, GlobalData’s forecast estimates that sales ... largest CRC market due to the high incidence of the ... with the 5EU, Japan, and China. Increased sales of CRC ...
Breaking Medicine News(10 mins):Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... can reduce hot flashes effectively. The good news is that cool ... , ... Ann Arbor, MI (PRWEB) July 21, 2008 -- The hot ... debating merits of synthetic or bio-identical hormones. Too much complicated information overwhelms ...
... New data from a study of patients with treatment-resistant ... subcallosal cingulate region (SCG or Cg25) of the brain ... significant improvement in patients as early as one month ... improvement over time. , The data are ...
... Eileen T. Kennedy DSc, Dean of Tufts University,s Gerald ... and Policy announced the 3rd Annual Friedman School Symposium, ... issues facing industry, policy-makers, academics and thought leaders in ... Boston, September 24th to 26th, 2008. , Fifteen experts ...
... iCAD, Inc. (Nasdaq:,ICAD), an industry-leading provider of ... its previously announced,agreement to purchase the principal assets ... in White Plains, NY. The,purchase price was $5 ... shares of iCAD common stock. The number of ...
... leucoanthocyanidins and anthocyanidins are natural, ... antioxidant properties, IRVINE, Calif., July 21 ... phytochemical reference standards and,contract research, announced today its ... agreement with The Research Foundation of the,State University ...
... PITTSBURGH, July 21 Mylan Inc. (NYSE: ... Crookshank as vice president -,Investor Relations and as ... to Chief Financial Officer Edward J. Borkowski, Crookshank ... as for the,development and direction of activities that ...
Cached Medicine News:Health News:Menopause: Hot Flashes Can Be Reduced 90% without Hormones 2Health News:Menopause: Hot Flashes Can Be Reduced 90% without Hormones 3Health News:Promising results in deep brain stimulation for patients with treatment-resistant depression 2Health News:Promising results in deep brain stimulation for patients with treatment-resistant depression 3Health News:'Nutrition Agenda 2008' is focus of Tufts Friedman School Symposium 2Health News:'Nutrition Agenda 2008' is focus of Tufts Friedman School Symposium 3Health News:iCAD Completes Acquisition of CAD Sciences 2Health News:ChromaDex Licenses Green Chemistry Technology to Manufacture a New Class of Super Fruit Compounds 2Health News:ChromaDex Licenses Green Chemistry Technology to Manufacture a New Class of Super Fruit Compounds 3Health News:Daniel E. Crookshank Joins Mylan as Vice President - Investor Relations 2
Ultra-Slip™ endotracheal tube guide for single-patient use only., ,Caution: Not MRI Compatible....
FlexiSlip™ Plastic coated malleable metal core. Single use, Sterile, Latex Free. Soft distal tip flexes to reduce risk of trauma to patient. Malleable metal core is easy to shape. Low friction ...
Endotracheal Tube Stylet- Adult, Copper, Malleable, Non-Sterile, Latex Free, Suitable for tubes 5.0 mm I.D. or larger....
... Requires minimal cervical spine manipulation. Prevent dental ... nasally. Cost effective alternative to X-ray. Light-guided ... the soft tissues in the neck. This ... of the trachea relative to the esophagus. ...
Medicine Products: